DOCSLIB.ORG

Perfluoroalkyl and Polyfluoroalkyl Substances and Women's Health: a Possible Etiology for Earlier Menopause and Accelerated R

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Perfluoroalkyl and Polyfluoroalkyl Substances and Women's Health: a Possible Etiology for Earlier Menopause and Accelerated R Perfluoroalkyl and Polyfluoroalkyl Substances and Women’s Health: A Possible Etiology for Earlier Menopause and Accelerated Reproductive Aging by Ning Ding A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Epidemiological Science) in The University of Michigan 2020 Doctoral Committee: Associate Professor Sung Kyun Park, Chair Professor Stuart Batterman Professor Siobán D. Harlow Professor Bhramar Mukherjee Professor John F. Randolph Jr. Ning Ding [email protected] ORCID iD: 0000-0001-5244-2909 © Ning Ding 2020 Dedication This work is wholeheartedly dedicated to my mother and father, Hong Wang and Zhili Ding, who are always positive role models in my life. They have not lived in the easiest of lives. And yet in the face of challenges and difficulties along the way, they have always pushed through and did what they had to do to make things work. They have taught me the importance of hard work, honesty and integrity, and always being humble in every situation, and never giving up. ii Acknowledgements First, I would like to sincerely thank my committee chair and lifelong mentor, Dr. Sung Kyun Park, whose encouragement, guidance and support from the initial to the final level of doctoral education. Dr. Park’s mentorship continuously inspires me to ask exciting research questions and pursue collaborative opportunities. I am sure it would have not been possible without his help. I am honestly thankful to my mentors, Dr. Siobán D. Harlow and Dr. John F. Randolph Jr., for their patient instructions, insightful comments, and strong support at every stage of my doctoral career. I am also grateful for my mentors, Dr. Stuart Batterman and Dr. Bhramar Mukherjee, who consistently helps me apply my research through an interdisciplinary lens. I would also like to acknowledge and extend my heartfelt gratitude to my peer students, staff in the Center for Midlife Science, and faculty at the University of Michigan School of Public Health who have made the completion of this dissertation possible. Finally, I must express my extreme gratitude to Xin Wang, my boyfriend and my colleague, who always gives me unlimited braveness and strength. I am so fortunate to have him by my side for the past seven years. Without him I can hardly overcome the obstacles I have met on my journey to the final degree. There are numerous funding sources that have been instrumental in supporting my doctoral studies which include grants from the National Institute of Environmental Health Sciences (NIEHS) R01-ES026578, R01-ES026964 and P30-ES017885, and by the Center for Disease Control and Prevention (CDC)/National Institute for Occupational Safety and Health (NIOSH) grant T42-OH008455. iii The Study of Women's Health Across the Nation (SWAN) has grant support from the National Institutes of Health (NIH), DHHS, through the National Institute on Aging (NIA), the National Institute of Nursing Research (NINR) and the NIH Office of Research on Women’s Health (ORWH) (Grants U01NR004061; U01AG012505, U01AG012535, U01AG012531, U01AG012539, U01AG012546, U01AG012553, U01AG012554, U01AG012495). The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the NIA, NINR, ORWH or the NIH. The SWAN Repository (U01AG017719). This publication was supported in part by the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 RR024131. Clinical Centers: University of Michigan, Ann Arbor – Siobán Harlow, PI 2011 – present, MaryFran Sowers, PI 1994-2011; Massachusetts General Hospital, Boston, MA – Joel Finkelstein, PI 1999 – present; Robert Neer, PI 1994 – 1999; Rush University, Rush University Medical Center, Chicago, IL – Howard Kravitz, PI 2009 – present; Lynda Powell, PI 1994 – 2009; University of California, Davis/Kaiser – Ellen Gold, PI; University of California, Los Angeles – Gail Greendale, PI; Albert Einstein College of Medicine, Bronx, NY – Carol Derby, PI 2011 – present, Rachel Wildman, PI 2010 – 2011; Nanette Santoro, PI 2004 – 2010; University of Medicine and Dentistry – New Jersey Medical School, Newark – Gerson Weiss, PI 1994 – 2004; and the University of Pittsburgh, Pittsburgh, PA – Karen Matthews, PI. NIH Program Office: National Institute on Aging, Bethesda, MD – Chhanda Dutta 2016- present; Winifred Rossi 2012–2016; Sherry Sherman 1994 – 2012; Marcia Ory 1994 – 2001; National Institute of Nursing Research, Bethesda, MD – Program Officers. iv Central Laboratory: University of Michigan, Ann Arbor – Daniel McConnell (Central Ligand Assay Satellite Services). SWAN Repository: University of Michigan, Ann Arbor – Siobán Harlow 2013 - Present; Dan McConnell 2011 - 2013; MaryFran Sowers 2000 – 2011. Coordinating Center: University of Pittsburgh, Pittsburgh, PA – Maria Mori Brooks, PI 2012 - present; Kim Sutton-Tyrrell, PI 2001 – 2012; New England Research Institutes, Watertown, MA - Sonja McKinlay, PI 1995 – 2001. Steering Committee: Susan Johnson, Current Chair Chris Gallagher, Former Chair We thank the study staff at each site and all the women who participated in SWAN. We also thank Drs. Antonia Calafat and Xiaoyun Ye at Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, for their support in PFAS assessment. v Table of Contents Dedication ....................................................................................................................................... ii Acknowledgements ........................................................................................................................ iii List of Tables ................................................................................................................................. ix List of Figures .............................................................................................................................. xiv Abstract ....................................................................................................................................... xvii Chapter I. Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) and Their Effects on the Ovary ......................................................................................................................................................... 1 Abstract ....................................................................................................................................... 2 1. Introduction ............................................................................................................................. 4 2. Methods ................................................................................................................................... 6 3. Basic principles of PFAS ........................................................................................................ 7 3.1 Nomenclature ..................................................................................................................... 7 3.2 Sources of human exposure ............................................................................................... 8 3.3 Transport and clearance of PFAS in the human body ..................................................... 11 4. Mechanistic evidence for ovarian toxicity of PFAS ............................................................. 13 4.1 Effects of PFAS on folliculogenesis ................................................................................ 13 4.2 Effects of PFAS on ovarian steroidogenesis ................................................................... 17 5. Epidemiologic evidence linking PFAS exposure and ovarian outcomes .............................. 20 5.1 Sex hormones .................................................................................................................. 21 5.2 Onset age of menarche .................................................................................................... 22 5.3 Menstrual cycle characteristics ........................................................................................ 23 5.4 Ovarian aging .................................................................................................................. 24 5.5 Other conditions .............................................................................................................. 26 6. Discussion ............................................................................................................................. 27 7. Conclusions ........................................................................................................................... 29 8. Specific aims ......................................................................................................................... 29 References ................................................................................................................................. 31 vi Chapter II. Longitudinal Trends in Perfluoroalkyl and Polyfluoroalkyl Substances among Midlife Women from 1999 to 2011: the Study of Women’s Health Across the Nation ........................... 75 Abstract ..................................................................................................................................... 76 1. Introduction ..........................................................................................................................
Load more

Recommended publications
  • Chemicals in the Fourth Report and Updated Tables Pdf Icon[PDF
    Chemicals in the Fourth National Report on Human Exposure to Environmental Chemicals: Updated Tables, March 2021 CDC’s Fourth National Report on Human Exposure to Environmental Chemicals: Updated Tables, March 2021 provides exposure data on the following chemicals or classes of chemicals. The Updated Tables contain cumulative data from national samples collected beginning in 1999–2000 and as recently as 2015-2016. Not all chemicals were measured in each national sample. The data tables are available at https://www.cdc.gov/exposurereport. An asterisk (*) indicates the chemical has been added since publication of the Fourth National Report on Human Exposure to Environmental Chemicals in 2009. Adducts of Hemoglobin Acrylamide Formaldehyde* Glycidamide Tobacco Alkaloids and Metabolites Anabasine* Anatabine* Cotinine Cotinine-n-oxide* Hydroxycotinine* Trans-3’-hydroxycotinine* 1-(3-Pyridyl)-1-butanol-4-carboxylic acid* Nicotine* Nicotine-N’-oxide* Nornicotine* Tobacco-Specific Nitrosamines (TSNAs) N’-Nitrosoanabasine (NAB)* N’-Nitrosoanatabine (NAT)* N’-Nitrosonornicotine (NNN)* Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol) (NNAL)* Volatile N-nitrosamines (VNAs) N-Nitrosodiethylamine (NDEA)* N-Nitrosoethylmethylamine (NMEA)* N-Nitrosomorpholine (NMOR)* N-Nitrosopiperidine (NPIP)* N-Nitrosopyrrolidine (NPYR)* Disinfection By-Products Bromodichloromethane Dibromochloromethane Tribromomethane (Bromoform) Trichloromethane (Chloroform) Personal Care and Consumer Product Chemicals and Metabolites Benzophenone-3 Bisphenol A Bisphenol F* Bisphenol
    [Show full text]
  • DRAFT Indicators Biomonitoring: Perfluorochemicals (Pfcs)
    America’s Children and the Environment, Third Edition DRAFT Indicators Biomonitoring: Perfluorochemicals (PFCs) EPA is preparing the third edition of America’s Children and the Environment (ACE3), following the previous editions published in December 2000 and February 2003. ACE is EPA’s compilation of children’s environmental health indicators and related information, drawing on the best national data sources available for characterizing important aspects of the relationship between environmental contaminants and children’s health. ACE includes four sections: Environments and Contaminants, Biomonitoring, Health, and Special Features. EPA has prepared draft indicator documents for ACE3 representing 23 children's environmental health topics and presenting a total of 42 proposed children's environmental health indicators. This document presents the draft text, indicator, and documentation for the PFCs topic in the Biomonitoring section. THIS INFORMATION IS DISTRIBUTED SOLELY FOR THE PURPOSE OF PRE- DISSEMINATION PEER REVIEW UNDER APPLICABLE INFORMATION QUALITY GUIDELINES. IT HAS NOT BEEN FORMALLY DISSEMINATED BY EPA. IT DOES NOT REPRESENT AND SHOULD NOT BE CONSTRUED TO REPRESENT ANY AGENCY DETERMINATION OR POLICY. For more information on America’s Children and the Environment, please visit www.epa.gov/ace. For instructions on how to submit comments on the draft ACE3 indicators, please visit www.epa.gov/ace/ace3drafts/. March 2011 DRAFT: DO NOT QUOTE OR CITE Biomonitoring: Perfluorochemicals 1 Perfluorochemicals (PFCs) 2 3 Perfluorochemicals (PFCs) are a group of manmade chemicals that have been used since the 4 1950s in many consumer products.1 The structure of these chemicals makes them very stable, 5 hydrophobic (water-repelling), and oleophobic (oil-repelling).
    [Show full text]
  • And Polyfluoroalkyl Substances – Chemical Variation and Applicability of Current Fate Models
    CSIRO PUBLISHING Environ. Chem. 2020, 17, 498–508 Research Paper https://doi.org/10.1071/EN19296 Investigating the OECD database of per- and polyfluoroalkyl substances – chemical variation and applicability of current fate models Ioana C. Chelcea,A Lutz Ahrens,B Stefan O¨ rn,C Daniel MucsD and Patrik L. Andersson A,E ADepartment of Chemistry, Umea˚ University, SE-901 87 Umea˚, Sweden. BDepartment of Aquatic Sciences and Assessment, Swedish University of Agricultural Sciences (SLU), Box 7050, SE-750 07 Uppsala, Sweden. CDepartment of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural Sciences (SLU), SE-750 07 Uppsala, Sweden. DRISE SP – Chemical and Pharmaceutical Safety, Forskargatan 20, 151 36 So¨derta¨lje, Sweden. ECorresponding author. Email: [email protected] Environmental context. A diverse range of materials contain organofluorine chemicals, some of which are hazardous and widely distributed in the environment. We investigated an inventory of over 4700 organofluorine compounds, characterised their chemical diversity and selected representatives for future testing to fill knowledge gaps about their environmental fate and effects. Fate and property models were examined and concluded to be valid for only a fraction of studied organofluorines. Abstract. Many per- and polyfluoroalkyl substances (PFASs) have been identified in the environment, and some have been shown to be extremely persistent and even toxic, thus raising concerns about their effects on human health and the environment. Despite this, little is known about most PFASs. In this study, the comprehensive database of over 4700 PFAS entries recently compiled by the OECD was curated and the chemical variation was analysed in detail.
    [Show full text]
  • Analytical Standards for Human Exposure Analysis
    ENVIRONMENTAL STANDARDS Cambridge Isotope Laboratories, Inc. isotope.com Analytical Standards for Human Exposure Analysis Human Personal Care Industrial Products Pollution Dermal Inhalation Ingestion Food Tobacco Products Drinking Water Pharmaceuticals Cambridge Isotope Laboratories, Inc. North America: 1.800.322.1174 [email protected] | International: +1.978.749.8000 [email protected] | fax: 1.978.749.2768 | isotope.com Cambridge Isotope Laboratories, Inc. | Analytical Standards for Human Exposure Analysis Analytical Standards for Human Exposure Analysis Exposomics is the study of the exposome and is a field that has been gaining attention as researchers focus not only on identifying contaminants present in the environment, but their effects on humans. The exposome encompasses an individual’s lifetime exposure to internal and external stresses, including environmental, dietary, and metabolic factors, to name a few. Cambridge Isotope Laboratories, Inc. (CIL) has and continues to produce standards that are used in many leading biomonitoring research projects, such as the US Centers for Disease Control and Prevention (CDC) “National Health and Nutrition Examination Survey (NHANES)” and the Japan National Institute for Environmental Studies (NIES) “Japan Environment and Children’s Study (JECS).” The CDC’s NHANES program is focused on assessing the health and nutritional status of both children and adults in the United States. There are several studies involved in this program, which is notable in that both interviews and physical examinations are factored in when compiling data. The first NHANES study was conducted from 1971-1975 and subsequent studies are continuing to this day. Additional information about the NHANES program can be found at www.cdc.gov/nchs/nhanes/index.htm.
    [Show full text]
  • Cross-Sectional Study of the Association Between Serum Perfluorinated Alkyl Acid Concentrations and Dental Caries Among US Adolescents (NHANES 1999–2012)
    Open access Research BMJ Open: first published as 10.1136/bmjopen-2018-024189 on 5 February 2019. Downloaded from Cross-sectional study of the association between serum perfluorinated alkyl acid concentrations and dental caries among US adolescents (NHANES 1999–2012) Nithya Puttige Ramesh,1 Manish Arora,2 Joseph M Braun1 To cite: Puttige Ramesh N, ABSTRACT Strengths and limitations of this study Arora M, Braun JM. Cross- Study objectives Perfluoroalkyl acids (PFAAs) are a class sectional study of the of anthropogenic and persistent compounds that may ► Our study contributes to a gap in the literature by association between serum impact some biological pathways related to oral health. perfluorinated alkyl acid examining the relationship between perfluoroalkyl The objective of our study was to estimate the relationship concentrations and dental caries acid exposure and dental caries prevalence among between dental caries prevalence and exposure to four among US adolescents (NHANES adolescents, which, to the best of our knowledge, PFAA: perfluorooctanoic acid (PFOA), perfluorononanoic 1999–2012). BMJ Open has not been examined before. 2019;9:e024189. doi:10.1136/ acid (PFNA), perfluorohexane sulfonic acid (PFHxS) and ► The strengths of our study include the large sample perfluorooctane sulfonic acid (PFOS) in a nationally bmjopen-2018-024189 size (2869 participants) and the nationally repre- representative sample of US adolescents. Prepublication history and sentative nature of the National Health and Nutrition ► Setting/Design We analysed cross-sectional data from additional material for this Examination Survey (NHANES). the National Health and Nutrition Examination Survey from paper are available online. To ► Although we adjusted for potential confounders, 1999 to 2012 for 12–19-year-old US adolescents.
    [Show full text]
  • PFAS MCL Technical Support Document
    ATTACHMENT 1 New Hampshire Department of Environmental Services Technical Background Report for the June 2019 Proposed Maximum Contaminant Levels (MCLs) and Ambient Groundwater Quality Standards (AGQSs) for Perfluorooctane sulfonic Acid (PFOS), Perfluorooctanoic Acid (PFOA), Perfluorononanoic Acid (PFNA), and Perfluorohexane sulfonic Acid (PFHxS) And Letter from Dr. Stephen M. Roberts, Ph.D. dated 6/25/2019 – Findings of Peer Review Conducted on Technical Background Report June 28, 2019 New Hampshire Department of Environmental Services Technical Background Report for the June 2019 Proposed Maximum Contaminant Levels (MCLs) and Ambient Groundwater Quality Standards (AGQSs) for Perfluorooctane sulfonic Acid (PFOS), Perfluorooctanoic Acid (PFOA), Perfluorononanoic Acid (PFNA), and Perfluorohexane sulfonic Acid (PFHxS) June 28, 2019 Table of Contents Abbreviations ................................................................................................................................................. i Acknowledgements ...................................................................................................................................... iii Section I. Executive Summary ....................................................................................................................... 1 Section II. Introduction ................................................................................................................................. 2 Section III. Reference Dose Derivation ........................................................................................................
    [Show full text]
  • Us 2018 / 0296525 A1
    UN US 20180296525A1 ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2018/ 0296525 A1 ROIZMAN et al. ( 43 ) Pub . Date: Oct. 18 , 2018 ( 54 ) TREATMENT OF AGE - RELATED MACULAR A61K 38 /1709 ( 2013 .01 ) ; A61K 38 / 1866 DEGENERATION AND OTHER EYE (2013 . 01 ) ; A61K 31/ 40 ( 2013 .01 ) DISEASES WITH ONE OR MORE THERAPEUTIC AGENTS (71 ) Applicant: MacRegen , Inc ., San Jose , CA (US ) (57 ) ABSTRACT ( 72 ) Inventors : Keith ROIZMAN , San Jose , CA (US ) ; The present disclosure provides therapeutic agents for the Martin RUDOLF , Luebeck (DE ) treatment of age - related macular degeneration ( AMD ) and other eye disorders. One or more therapeutic agents can be (21 ) Appl. No .: 15 /910 , 992 used to treat any stages ( including the early , intermediate ( 22 ) Filed : Mar. 2 , 2018 and advance stages ) of AMD , and any phenotypes of AMD , including geographic atrophy ( including non -central GA and Related U . S . Application Data central GA ) and neovascularization ( including types 1 , 2 and 3 NV ) . In certain embodiments , an anti - dyslipidemic agent ( 60 ) Provisional application No . 62/ 467 ,073 , filed on Mar . ( e . g . , an apolipoprotein mimetic and / or a statin ) is used 3 , 2017 . alone to treat or slow the progression of atrophic AMD Publication Classification ( including early AMD and intermediate AMD ) , and / or to (51 ) Int. CI. prevent or delay the onset of AMD , advanced AMD and /or A61K 31/ 366 ( 2006 . 01 ) neovascular AMD . In further embodiments , two or more A61P 27 /02 ( 2006 .01 ) therapeutic agents ( e . g ., any combinations of an anti - dys A61K 9 / 00 ( 2006 . 01 ) lipidemic agent, an antioxidant, an anti- inflammatory agent, A61K 31 / 40 ( 2006 .01 ) a complement inhibitor, a neuroprotector and an anti - angio A61K 45 / 06 ( 2006 .01 ) genic agent ) that target multiple underlying factors of AMD A61K 38 / 17 ( 2006 .01 ) ( e .
    [Show full text]
  • Health Effects Support Document for Perfluorooctanoic Acid (PFOA)
    United States Office of Water EPA 822-R-16-003 Environmental Protection Mail Code 4304T May 2016 Agency Health Effects Support Document for Perfluorooctanoic Acid (PFOA) Perfluorooctanoic Acid – May 2016 i Health Effects Support Document for Perfluorooctanoic Acid (PFOA) U.S. Environmental Protection Agency Office of Water (4304T) Health and Ecological Criteria Division Washington, DC 20460 EPA Document Number: 822-R-16-003 May 2016 Perfluorooctanoic Acid – May 2016 ii BACKGROUND The Safe Drinking Water Act (SDWA), as amended in 1996, requires the Administrator of the U.S. Environmental Protection Agency (EPA) to periodically publish a list of unregulated chemical contaminants known or anticipated to occur in public water systems and that may require regulation under SDWA. The SDWA also requires the Agency to make regulatory determinations on at least five contaminants on the Contaminant Candidate List (CCL) every 5 years. For each contaminant on the CCL, before EPA makes a regulatory determination, the Agency needs to obtain sufficient data to conduct analyses on the extent to which the contaminant occurs and the risk it poses to populations via drinking water. Ultimately, this information will assist the Agency in determining the most appropriate course of action in relation to the contaminant (e.g., developing a regulation to control it in drinking water, developing guidance, or deciding not to regulate it). The PFOA health assessment was initiated by the Office of Water, Office of Science and Technology in 2009. The draft Health Effects Support Document for Perfluoroctanoic Acid (PFOA) was completed in 2013 and released for public comment in February 2014.
    [Show full text]
  • Priority Pollutant, Endocrine Disruptor, and Chemical Contaminant Standards Solutions for a Greener World Introduction
    Priority Pollutant, Endocrine Disruptor, and Chemical Contaminant Standards Solutions for a Greener World Introduction Priority Pollutant, Endocrine Disruptor, and Chemical Contaminant Standards isotope.com Pharmaceutical and Personal Care Product Halogenated and Substituted Benzene Standards and Phenol Standards Concern about environmental and human exposure to Many industrial and consumer products are composed of pharmaceuticals and personal care products (PPCPs) has grown chemicals that contain halogenated or substituted benzene significantly. This classification encompasses a broad range of or phenol functional groups. Resistant to decomposition and chemicals, ranging from antibiotics to hormones to pesticides. metabolism, these chemicals may persist even after the parent One common theme among these groups is the need for molecule has undergone partial decomposition, or they may high-quality isotopically labeled standards to strengthen the exist as a product or an industrial byproduct. The increased analysis of PPCPs in difficult matrices such as sewage sludge use of brominated compounds is expected to lead to more and wastewater. CIL, with guidance from leading laboratories brominated benzenes and phenols in the environment, and around the world, works diligently to produce representative the continued presence of chlorinated compounds ensures standards for the analysis of PPCPs. that chlorinated benzenes and phenols will be found in the environment for years to come. Food and Drinking Water Analysis Standards Bisphenol Standards Increased attention to possible contamination of food and Bisphenol A (BPA) is a synthetic compound that has long been water has caused analysts to broaden the scope of trace food used in the production of polycarbonate plastics and epoxy and water testing by IDMS.
    [Show full text]
  • United Nations Sc
    UNITED NATIONS SC UNEP/POPS/POPRC.12/INF/16 Distr.: General 2 August 2016 English only Stockholm Convention on Persistent Organic Pollutants Persistent Organic Pollutants Review Committee Twelfth meeting Rome, 19–23 September 2015 Item 4 (d) of the provisional agenda Technical work: consolidated guidance on alternatives to perfluorooctane sulfonic acid and its related chemicals Comments and responses relating to the draft consolidated guidance on alternatives to perfluorooctane sulfonic acid and its related chemicals Note by the Secretariat As referred to in the note by the Secretariat on guidance on alternatives to perfluorooctane sulfonic acid and its related chemicals (UNEP/POPS/POPRC.12/7), the annex to the present note contains a table listing the comments and responses relating to the draft guidance. The present note, including its annex, has not been formally edited. UNEP/POPS/POPRC.12/1. 030816 UNEP/POPS/POPRC.12/INF/16 Annex Comments and responses relating to the draft consolidated guidance on alternatives to perfluorooctane sulfonic acid and its related chemicals Minor grammatical or spelling changes have been made without acknowledgment. Only substantial comments are listed. Yellow highlight indicates addition of text while green highlight indicates deletion. Source of Page Para Comments on the second draft Response Comment Austria 7 2 This statement is better placed in Chapter VII Rejected. accompanied with a justification for those “critical applications”. For clarification “where it is not currently possible without the use of PFOS” is added Austria 15 47 According to May be commercialized is revised to http://poppub.bcrc.cn/col/1413428117937/index.html “are commercialized” F-53 and F-53B have a long history of usage and have been commercialized before PFOS related Reference substances were used (cf.
    [Show full text]
  • Recommendation on Perfluorinated Compound Treatment Options for Drinking Water
    Recommendation on Perfluorinated Compound Treatment Options for Drinking Water New Jersey Drinking Water Quality Institute Treatment Subcommittee June 2015 Laura Cummings, P.E., Chair Anthony Matarazzo Norman Nelson, P.E. Fred Sickels Carol T. Storms Background At the request of the Commissioner of the New Jersey Department of Environmental Protection the Drinking Water Quality Institute (DWQI) is working to develop recommended Maximum Contaminant Levels (MCL) for three long-chain perfluorinated compounds (PFC): Perfluorononanoic acid (PFNA), Perfluorooctanoic acid (PFOA) and Perfluorooctanesulfonic acid (PFOS). The Treatment Subcommittee of the Drinking Water Quality Institute is responsible for identifying available treatment technologies or methods for removal of hazardous contaminants from drinking water. The subcommittee has met several times over the last year beginning in July 2014 to discuss and investigate best available treatment options for the long-chain (8 – 9 carbon) PFCs identified above. The subcommittee decided to research and report on treatment options for all three compounds, as the treatment options are not expected to differ from compound to compound due to their similar properties (e.g. persistence, water solubility, similar structure, strong carbon-fluorine bonds, and high polarity). This approach contrasts with the other two subcommittees which will address the three compounds separately. The subcommittee has gathered and reviewed data from several sources in order to identify widely-accepted and well-performing strategies for removal of long-chain PFCs, including use of alternate sources. This report is intended to present the subcommittee’s findings. At this time, there are no Federal drinking water standards for PFNA, PFOA or PFOS; however in 2009 the United State Environmental Protection Agency (USEPA, 2009) established a Provisional Health Advisory (PHA) level of 0.4 µg/L for PFOA and 0.2 µg/L PHA for PFOS for short-term exposure.
    [Show full text]
  • Perfluorochemicals (Pfcs)
    Biomonitoring | Perfluorochemicals (PFCs) Perfluorochemicals (PFCs) Perfluorochemicals (PFCs) are a group of synthetic chemicals that have been used in many consumer products.1 The structure of these chemicals makes them very stable, hydrophobic (water-repelling), and oleophobic (oil-repelling). These unique properties have led to extensive use of PFCs in surface coating and protectant formulations for paper and cardboard packaging products; carpets; leather products; and textiles that repel water, grease, and soil. PFCs have also been used in fire-fighting foams and in the production of nonstick coatings on cookware and some waterproof clothes.1 Due in part to their chemical properties, some PFCs can remain in the environment and bioconcentrate in animals.2-8 Data from human studies suggest that some PFCs can take years to be cleared from the body.9-13 The PFCs with the highest production volumes in the United States have been perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA).1 PFOS and PFOA are also two of the most frequently detected PFCs in humans.14 Other PFCs include perfluorohexane sulfonic acid (PFHxS), which is a member of the same chemical category as PFOS; and perfluorononanoic acid (PFNA), which is a member of the same chemical category as PFOA.15 Chemicals within a given PFC chemical category share similar chemical structures and uses. Although some studies have addressed PFHxS and PFNA specifically, the majority of scientific research has focused on PFOS and PFOA.15 In 2000, one of the principal perfluorochemical manufacturers, 3M, began phasing out the production of PFOA, PFOS, and PFOS-related compounds. The 3M phaseout of PFOS and PFHxS was completed in 2002, and its phaseout of PFOA was completed in 2008.16 In 2006, to address PFOA production by other manufacturers, EPA launched the 2010/15 PFOA Stewardship Program, with eight companies voluntarily agreeing to reduce emissions and product content of PFOA, PFNA, and related chemicals by 95% no later than 2010.
    [Show full text]